73 results on '"A. Bodzenta-Lukaszyk"'
Search Results
2. Efficacy of ciclesonide in the treatment of patients with asthma exacerbation
3. Zonulin, inflammation and iron status in patients with early stages of chronic kidney disease
4. Fibroblast growth factor 23, iron and inflammation – are they related in early stages of chronic kidney disease?
5. Asthma is associated with reduced fibrinolytic activity, abnormal clot architecture, and decreased clot retraction rate
6. High-dose bee venom exposure induces similar tolerogenic B-cell responses in allergic patients and healthy beekeepers
7. Reduced clot retraction rate and altered platelet energy production in patients with asthma
8. GDF-15, iron, and inflammation in early chronic kidney disease among elderly patients
9. Circulating classical CD14++CD16− monocytes predict shorter time to initial treatment in chronic lymphocytic leukemia patients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163
10. Endothelial progenitor cell levels in juvenile idiopathic arthritis patients; effects of anti-inflammatory therapies
11. Association Between IL-13 -1112 C/T Promoter Polymorphism and Patterns of Allergen-Induced Asthmatic Response in House Dust Mite Allergic Patients
12. Vitamin D3 Treatment Decreases Frequencies of CD16-Positive and TNF-α-Secreting Monocytes in Asthmatic Patients
13. Development of Asthmatic Response upon Bronchial Allergen Challenge Is Associated with Dynamic Changes of Interleukin-10-Producing and Interleukin-10-Responding CD4+ T Cells
14. Delayed diagnosis of human immunodeficiency virus infection in a patient with non-specific neurological symptoms and pancytopenia: a case report
15. Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension
16. Synergistic Effect Of Dermatophagoides Pteronyssinus Allergens and Dexamethasone On Expression Of CD163 By Peripheral Blood Mononuclear Cells Of Allergic Asthma Patients
17. Omalizumab treatment in brittle asthma
18. Alterations of monocyte subsets in chronic heart failure patients in association with changes in epigenetic regulation
19. Clinical Effectiveness of Hymenoptera Venom Immunotherapy: A Prospective Observational Multicenter Study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity
20. Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial
21. Lower proportions of CD4+CD25highand CD4+FoxP3, but not CD4+CD25+CD127lowFoxP3+T cell levels in children with autoimmune thyroid diseases
22. Decreased CD127 Expression on CD4+ T-Cells and Elevated Frequencies of CD4+CD25+CD127− T-Cells in Children with Long-Lasting Type 1 Diabetes
23. Phenotypic Correlations between Monocytes and CD4+ T Cells in Allergic Patients
24. Fluticasone/Formoterol Combination Therapy versus Budesonide/Formoterol for the Treatment of Asthma: A Randomized, Controlled, Non-Inferiority Trial of Efficacy and Safety
25. Onset of Bronchodilation with Fluticasone/Formoterol Combination Versus Fluticasone/Salmeterol in an Open-Label, Randomized Study
26. Allergen Challenge Differentially Affects the Number of Circulating Monocyte Subsets
27. Kombinationstherapie mit Fluticason/Formoterol in einem Dosieraerosol hat vergleichbare Wirksamkeit wie die freie Kombination Fluticason und Formoterol
28. Vergleich der Kombination Fluticason/Formoterol in einem Dosieraerosol mit der Kombination Budesonid/Formoterol zur Therapie des Asthmas: Eine Nichtunterlegenheitsstudie
29. Efficacité de fluticasone/formotérol vs composants administrés séparément
30. Association de fluticasone/formotérol vs budésonide/formotérol pour le traitement de l’asthme : étude de non-infériorité
31. Inflammatory Markers and Acid-Base Equilibrium in Exhaled Breath Condensate of Stable and Unstable Asthma Patients
32. Airway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy
33. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study
34. Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler
35. Concentrations of plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in induced sputum of asthma patients after allergen challenge.
36. Eotaxin in Exhaled Breath Condensate of Allergic Asthma Patients with Exercise-Induced Bronchoconstriction
37. RANTES in Exhaled Breath Condensate of Patients with Severe Persistent Allergic Asthma during Omalizumab Therapy
38. P177 Fluticasone propionate/formoterol fumarate combination therapy is as effective as fluticasone propionate/salmeterol xinafoate in the treatment of asthma: a randomised controlled trial
39. P24 Fluticasone propionate/formoterol fumarate combination therapy has a more rapid onset of action than fluticasone propionate/salmeterol xinafoate in the treatment of asthma: a randomised controlled trial
40. Eotaxin-1 in exhaled breath condensate of stable and unstable asthma patients.
41. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: The importance of baseline serum tryptase†
42. Effects of Oral Glucocorticoid Therapy on CD4+CD25+CD127- and CD4+CD25high T Cell Levels in Asthmatic Patients
43. Anti-IgE Therapy with Omalizumab Decreases Endothelin-1 in Exhaled Breath Condensate of Patients with Severe Persistent Allergic Asthma
44. Changes in High-Sensitivity C-Reactive Protein in Serum and Exhaled Breath Condensate after Intensive Exercise in Patients with Allergic Asthma
45. RANTES in Exhaled Breath Condensate of Allergic Asthma Patients with Exercise-Induced Bronchoconstriction
46. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: Importance of baseline serum tryptase—a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity
47. Enhanced frequencies of CD14++CD16+, but not CD14+CD16+, peripheral blood monocytes in severe asthmatic patients
48. High-sensitivity C-reactive protein in the exhaled breath condensate and serum in stable and unstable asthma
49. Oral glucocorticoid treatment decreases interleukin-10 receptor expression on peripheral blood leucocyte subsets
50. Exhaled Nitric Oxide in Evaluation of Young Adults with Chronic Cough
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.